Pharmacodynamics of Imipenem in Combination with β-Lactamase Inhibitor MK7655 in a Murine Thigh Model
2014 · Antimicrobial Agents and Chemotherapy · 46 citations
https://doi.org/10.1128/aac.03706-14
M
Mary Motyl
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
184
Papers
6.6K
Citations
42
h-index
95
i10-index
Mary Motyl is an academic researcher from Merck & Co., Inc., Rahway, NJ, USA (United States). The author has contributed to research in topics: Antibiotic Resistance in Bacteria & Antibiotic Use and Resistance & Antibiotics Pharmacokinetics and Efficacy. The author has an h-index of 42, co-authored 157 publications.
ORCID: 0000-0003-3142-8475Papers by this author
worksIn Vitro Activity of Oral Antimicrobial Agents against Pathogens Associated with Community-Acquired Upper Respiratory Tract and Urinary Tract Infections: A Five Country Surveillance Study
2016 · Infectious Diseases and Therapy · 15 citations
https://doi.org/10.1007/s40121-016-0112-3
Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018–2020
2023 · BMC Microbiology · 15 citations
https://doi.org/10.1186/s12866-023-02864-3
Antimicrobial Activity of Imipenem/Relebactam and Comparator Agents Against Gram-Negative Isolates Collected From Pediatric Patients: SMART 2018–2022 Global Surveillance
2025 · Journal of the Pediatric Infectious Diseases Society · 1 citations
https://doi.org/10.1093/jpids/piae134
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat